Buscar
Congreso SOLACI
HomeACC 2013.Day 2

Day 2

Ver Categoría
Day 2

Possible benefit for patients with acute myocardial infarction but without ventricular dysfunction.

Background: To evaluate whether the administration of eplerenone 24 hours after an acute myocardial infarction (AMI) in...
solaci -
Ver más
Day 2

SELECT ACS: The Inclacumab seems to reduce myocardial injury post angioplasty

P-selectin is an adhesion molecule involved in the interactions between endothelial cells, platelets and leukocytes. Inclacumab is...
solaci -
Ver más
Day 2

Possible benefit for patients with acute myocardial infarction but without ventricular dysfunction.

Background: To evaluate whether the administration of eplerenone 24 hours after an acute myocardial infarction (AMI) in...
solaci -
Ver más
Day 2

CHAMPION PHOENIX: Cangrelor compared with clopidogrel improves efficiency without increasing bleeding in patients undergoing angioplasty

Background: Oral antiplatelet agents have a limitation in their duration of action and bioavailability. Cangrelor is an...
solaci -
Ver más
Day 2

PARTNER 2: Edwards SAPIEN XT is even better. Results for PARTNER II, cohort B.

In the PARTNER 1 study, patients with inoperable severe aortic stenosis treated with an aortic valve prosthesis...
solaci -
Ver más
Day 2

STREAM trial: It is time to check out facilitated angioplasty?

It is not clear so far whether pre-hospital fibrinolysis with early angiography could provide a clinical outcome...
solaci -
Ver más
Day 2

DKCRUSH-III: Crushing versus Culotte technique for left main coronary artery

Angioplasty of the unprotected distal left main coronary artery with 2 stents presents the less favorable results...
solaci -
Ver más
Day 2

NEXT trial looked at a non-inferiority degradable polymer stent versus a second-generation permanent polymer stent.

Previous studies of non-inferiority (SORT-OUT III and V) compared the biodegradable polymer biolimus-eluting stent (BES) with permanent...
solaci -
Ver más

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

TricValve Transcatheter Bicaval Valve System for Severe Tricuspid Insufficiency: Events at One Year

Dr. Omar Tupayachi - 0
TricValve is the first bicaval valve system to obtain CE-Mark approval. This device heterotopic device eliminates tricuspid insufficiency reflux into the venous system, reducing...

Long Term Results of the International Chimney Registry

Dr. Omar Tupayachi - 0
The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

Dr. Omar Tupayachi - 0
The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

Noticias Institucionales

Hemodynamics and Interventional Cardioangiology Hybrid Training Course SOLACI-CACI

solaci - 0
We are now open for registration to the hybrid training course on Hemodynamics and Interventional Cardioangiology for Technicians and Nurses SOLACI-CACI 2025 Find all course...

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad